One round of SELEX for the generation of DNA aptamers directed against KLK6

Abstract Kallikrein-related peptidase 6 (KLK6) is an active serine protease that has been implicated in common pathologies, including neurodegenerative disorders such as Parkinson and Alzheimer disease and certain types of cancer. Antibodies, either polyclonal or monoclonal, that exhibit specificity for distinct members of the extended kallikrein family, including KLK6, were developed. With the exception of KLK3/PSA, the identification and generation of aptamers, as potential new tools with improved characteristics demanded for therapeutic and diagnostic applications, has not been explored for KLKs. Here, we report for the first time the identification of novel DNA aptamers against KLK6 that were isolated using a modified systemic evolution of ligands by exponential enrichment technique. The identified aptamers were characterized using fluorescence spectroscopy, competition ELISA, and quartz crystal microbalance, and two aptamers (008 and 022) were found to exhibit high affinity (Kd in the low nanomolar range) for KLK6. Aptamers were tested for their ability to bind to serum albumin, to demonstrate their specificity for their target, and the possible involvement of such proteins in the transport of aptamers into the bloodstream. The developed aptamers are expected to assist the development of novel diagnostic, biosensing, and therapeutic strategies.

[1]  Yoshikazu Nakamura,et al.  Selection of RNA aptamers against mouse embryonic stem cells. , 2012, Biochimie.

[2]  Tsutomu Hashikawa,et al.  Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. , 2003, Human molecular genetics.

[3]  Anthony D. Keefe,et al.  Building oligonucleotide therapeutics using non-natural chemistries. , 2006, Current opinion in chemical biology.

[4]  M. Menéndez-González,et al.  Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[5]  S. Tope,et al.  Aptamers as therapeutics , 2013 .

[6]  Selection of RNA aptamers specific to active prostate-specific antigen , 2010, Biotechnology Letters.

[7]  Takayuki Takahashi,et al.  Implications of protease M/neurosin in myelination during experimental demyelination and remyelination , 2006, Neuroscience Letters.

[8]  A. Perkins,et al.  Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. , 2009, Nuclear medicine and biology.

[9]  J. Clements,et al.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.

[10]  Hans Wolf,et al.  An aptamer-based quartz crystal protein biosensor. , 2002, Analytical chemistry.

[11]  Poul Nissen,et al.  Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. , 2010, Journal of structural biology.

[12]  J. Shaw,et al.  Modified deoxyoligonucleotides stable to exonuclease degradation in serum. , 1991, Nucleic acids research.

[13]  Sotiris Missailidis,et al.  New trends in aptamer-based electrochemical biosensors , 2009 .

[14]  Robert Giegerich,et al.  RNAshapes: an integrated RNA analysis package based on abstract shapes. , 2006, Bioinformatics.

[15]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[16]  W. James,et al.  Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery. , 2001, Current opinion in pharmacology.

[17]  D. Katsaros,et al.  Parallel overexpression of seven kallikrein genes in ovarian cancer. , 2003, Cancer research.

[18]  R. Godoy-Ruiz,et al.  The efficiency of different salts to screen charge interactions in proteins: a Hofmeister effect? , 2004, Biophysical journal.

[19]  M. Fehlings,et al.  Dynamic role of kallikrein 6 in traumatic spinal cord injury , 2006, The European journal of neuroscience.

[20]  Milan N Stojanovic,et al.  Aptamer-based colorimetric probe for cocaine. , 2002, Journal of the American Chemical Society.

[21]  À. Bayés,et al.  Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation , 2004, Biological chemistry.

[22]  E. Diamandis,et al.  Functional Roles of Human Kallikrein-related Peptidases* , 2009, The Journal of Biological Chemistry.

[23]  G. Yousef,et al.  Human kallikrein 6 as a biomarker of alzheimer's disease. , 2000, Clinical biochemistry.

[24]  A. Vlahou,et al.  A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. , 2009, Cancer research.

[25]  A. Perkins,et al.  Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. , 2007, Bioconjugate chemistry.

[26]  J. Clements,et al.  Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4* , 2000, The Journal of Biological Chemistry.

[27]  Takayuki Takahashi,et al.  Differential expression of neuropsin and protease M/neurosin in oligodendrocytes after injury to the spinal cord , 2004, Glia.

[28]  S. Mok,et al.  A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer , 1996, Molecular medicine.

[29]  J. Gariépy,et al.  DNA aptamers against the MUC1 tumour marker: design of aptamer–antibody sandwich ELISA for the early diagnosis of epithelial tumours , 2008, Analytical and bioanalytical chemistry.

[30]  Beth A. Cloud,et al.  Functional Role of Kallikrein 6 in Regulating Immune Cell Survival , 2011, PloS one.

[31]  Moses Rodriguez,et al.  Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease , 2004, The FASEB Journal.

[32]  Koichi Abe,et al.  Selection of DNA aptamer against prostate specific antigen using a genetic algorithm and application to sensing. , 2010, Biosensors & bioelectronics.

[33]  E. Diamandis,et al.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration , 2008, Biological chemistry.

[34]  Dílson Silva,et al.  The interaction of methyl-parathion with serum and albumin of the neo-tropical fish Piaractus mesopotamicus. , 2010, Ecotoxicology and environmental safety.

[35]  À. Bayés,et al.  The Structure of Human Prokallikrein 6 Reveals a Novel Activation Mechanism for the Kallikrein Family* , 2002, The Journal of Biological Chemistry.

[36]  D. Bunka,et al.  Aptamers come of age – at last , 2006, Nature Reviews Microbiology.

[37]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[38]  E. Diamandis,et al.  The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6) , 2012, Clinical chemistry and laboratory medicine.

[39]  Debasis Samanta,et al.  Immobilization of bio-macromolecules on self-assembled monolayers: methods and sensor applications. , 2011, Chemical Society reviews.

[40]  J. Hope,et al.  Characterization of 2′-Fluoro-RNA Aptamers That Bind Preferentially to Disease-associated Conformations of Prion Protein and Inhibit Conversion* , 2003, Journal of Biological Chemistry.

[41]  Volker A Erdmann,et al.  Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. , 2004, Nucleic acids research.

[42]  A. Perkins,et al.  Update: aptamers as novel radiopharmaceuticals: their applications and future prospects in diagnosis and therapy. , 2007, Cancer biotherapy & radiopharmaceuticals.

[43]  M. Morra,et al.  Assessment of inner filter effect corrections in fluorimetry , 1991 .